trial

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCTId NCT03345979
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 200 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2019-03-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-11-15
Primary completion
2019-03-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AripiprazolePaliperidone

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Sanjeev Pathak, MDStudy Director

Sites

16 total
Little Rock, United StatesRogers, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesHialeah, United StatesChicago, United StatesHoffman Estates, United StatesFlowood, United StatesSt Louis, United StatesLas Vegas, United States

Linked catalysts

1
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of — primary completion2019-03-12

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE3
Primary Completion Date
2019-03-12
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Paliperidone
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Sanjeev Pathak, MD
person